United States: Case Or Controversy Exists In Declaratory Judgment Action Of Non-Infringement For Disclaimed Patent

Apotex Inc., v. Daiichi Sankyo, Inc., No. 2014-1282, -1291, 2015 U.S. App. LEXIS 5134 (Fed. Cir. Mar. 31, 2015) (Taranto, J.). Click Here for a copy of the opinion.

Daiichi filed an NDA for olmesarta medoxomil (Benicar), a hypertension drug, and listed two of its patents, U.S. Pat. Nos. 5,616,599 and 6,878,703, in the Orange Book. Subsequently, Mylan filed an ANDA with a paragraph IV Certification, seeking to market a generic version of Benicar. Daiichi responded in part by disclaiming all claims of the '703 patent and requesting its removal ("delisting") from the Orange Book, which the FDA has not yet done.

Daichii initiated Hatch-Waxman litigation against Mylan. After a full trial, the district court upheld the validity of the '599 patent and entered judgment of infringement against Mylan. Consequently, the earliest Mylan can enter the market is October 25, 2016, six months after the expiration date of the '599 patent (which include 6 months of Patent Term Extension). In addition, because Mylan was the first ANDA filer to maintain a Paragraph IV Certification regarding the '703 patent, Mylan claims a 180-day exclusivity period starting on Oct. 25, 2016. 21 U.S.C. § 355(j)(5)(B)(iv)(II)(bb). Mylan benefits from this exclusivity period despite Daiichi's disclaimer and regarding the still Orange Book listed '703 patent.

Apotex filed an ANDA with a Paragraph III Certification (conceding validity and infringement of the '599 patent) and Paragraph IV Certification (alleging non-infringement of the '703 patent). Daichii did not sue on the disclaimed '703 patent. Apotex then brought a declaratory judgment action against Daiichi alleging that the Apotex product could not infringe the disclaimed '703 patent. Mylan moved to intervene, which the court denied. The district court dismissed Apotex's declaratory judgment claims, finding there could be no case or controversy over a disclaimed patent.

On appeal, the Federal Circuit reversed on both the denial of Mylan's intervention and the dismissal of Apotex's declaratory judgment action. Mylan has a right to be a party in this case because Apotex's declaratory judgment, if granted, would cause a forfeiture of Mylan's presumed market-exclusivity period. Therefore Mylan has a concrete monetary interest in the outcome of the case.

In holding that there was a sufficient case or controversy, the Court concluded: "the stakes over which the parties are vigorously fighting are concrete and substantial: the amount of revenue there will be from sales of olmesartan medoxomil, and who will get what portions of it, during a period of at least six months." Daiichi and Apotex also have concrete interests in the truncation or preservation of Mylan's exclusivity period.

The Court also reasoned that Apotex's delayed entry to the market (after Mylan) was "fairly traceable" to Daiichi's listing of the '703 patent in the Orange Book. If Daiichi never listed the '703 patent, Mylan would have no exclusivity period, since it lost its challenge to the '599 patent. Daiichi, therefore, was responsible for Mylan's exclusivity period.

Tentative FDA approval for Apotex's proposed drug was not a necessary predicate for Apotex to have a ripe case or controversy in connection with its patent dispute with Daiichi. Specifically, "the statute authorizing the litigation upon filing of an ANDA nowhere requires tentative FDA approval as a precondition: the filing of the ANDA, with a Paragraph IV Certification, is itself deemed an act of infringement." In addition, the patent owner must bring suit within 45 days to obtain a 30-month delay in any effective date of approval for the ANDA. Evidently, the statute "contemplates litigation well before such tentative approval."

Finally, the Court concluded that a declaratory judgment could "redress" the harm to Apotex, i.e., it could ultimately cause a forfeiture of Mylan's 180-day exclusivity period. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) added several forfeiture provisions relating to the 180-day first filer exclusivity. As applied to this case, forfeiture requires: (1) "the court must have entered a final decision of non-infringement that is no longer appealable"; and (2) "the second filer [Apotex] must have received tentative approval." If the first filer failed to enter the market within 75 days after these two requirements are satisfied, it is said to have forfeited its exclusivity rights. Therefore, Apotex could cause a forfeiture by obtaining a declaratory judgment and receiving a tentative approval before the date when Mylan has FDA approval to make its first sale. The Court also rejected Mylan's argument that tentative approval must precede the declaratory judgment action.

Because a case or controversy existed for all of these reasons, the Federal Circuit reversed.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.